European Hematology Association (EHA) and the European Myeloma Network (EMN) Include Pepaxti in New Clinical Practice Guidelines for Relapsed/Refractory Multiple Myeloma (RRMM) (https://www.myeloma.org/news-events/multiple-myeloma-news/eha-emn-pepaxti-for-rrmm)